Danny Rischin, MD, on High-Risk CSCC: Adjuvant Therapy

Posted: Friday, June 6, 2025

Danny Rischin, MD, of Peter MacCallum Cancer Centre, reviews phase III results on the efficacy of the PD-1–targeting monoclonal antibody cemiplimab-rwlc vs placebo as adjuvant therapy for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6001).

---